<- Go Home
HemaCare Corporation
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States.
Market Cap
$346.5M
Volume
10.1K
Cash and Equivalents
$10.9M
EBITDA
$8.3M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$18.5M
Profit Margin
52.89%
52 Week High
$26.23
52 Week Low
$8.62
Dividend
N/A
Price / Book Value
13.07
Price / Earnings
50.39
Price / Tangible Book Value
13.07
Enterprise Value
N/A
Enterprise Value / EBITDA
N/A
Operating Income
$7.4M
Return on Equity
31.55%
Return on Assets
17.47
Cash and Short Term Investments
$10.9M
Debt
$269.0K
Equity
$26.4M
Revenue
$34.9M
Unlevered FCF
-$6.2M
Sector
Health Care Providers and Services
Category
N/A